The impact of cancer therapy on cognition in the elderly

22Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Cancer and cancer therapy-related cognitive impairment (formerly known as chemobrain or chemo-fog) are often described in the literature. In the past, studies have failed to prove the existence of cancer therapy-related cognitive dysfunction. However, more recently, prospective trials have shown that patients undergoing chemotherapy do display impairment in specific cognitive domains. Aging confers an increased risk of developing cancer, as well as cognitive impairment. The Geriatric Oncology clinic of the Segal Cancer Centre, Jewish General Hospital in Montreal was founded in 2006 to address the unique needs of older cancer patients. We will describe two cases of cancer therapy-related cognitive impairment from our Geriatric Oncology clinic. The first case is that of a 75 year old male diagnosed with stage III non-small cell lung carcinoma who complained of forgetfulness since starting carboplatin-paclitaxel. The second case is that of a 65 year old female diagnosed with stage I, estrogen-receptor-positive breast cancer who had undergone lumpectomy followed by adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapy, radiation therapy and was on exemestane when she was evaluated. We will also briefly review the literature of cancer therapy-related cognitive impairment. © 2013 Mandilaras, Wan-Chow-Wah, Monette, Gaba, Monette and Alfonso.

Cite

CITATION STYLE

APA

Mandilaras, V., Wan-Chow-Wah, D., Monette, J., Gaba, F., Monette, M., & Alfonso, L. (2013). The impact of cancer therapy on cognition in the elderly. Frontiers in Pharmacology, 4 APR. https://doi.org/10.3389/fphar.2013.00048

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free